Delivery Order SPE2DB22D3501-SPE2DB25FWV60
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,677.88 to AmerisourceBergen Drug Corp for the supply of IPOL Vial 5ML pharmaceutical products. This firm fixed-price, competitively awarded delivery order was issued on July 23, 2025, with an ultimate completion date of July 24, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating AmerisourceBergen Drug Corp...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,090.10 to AmerisourceBergen Drug Corp for a 5mL vial of Ipol (polio vaccine) on July 22, 2025, with an ultimate completion date of July 23, 2025. This delivery order was competitively awarded with firm fixed pricing and no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. This delivery order is a child contract issued...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,870.10 on August 4, 2025, for the supply of IPOL Vial 5ML pharmaceutical product. The contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support...
- The Defense Logistics Agency Troop Support Medical awarded a $273,510 firm fixed price delivery order to Amerisourcebergen Drug Corporation for IPOL vials. The order is for 4561322355 5mL vials of IPOL to be delivered to Amerisourcebergen's facility in Conshohocken, Pennsylvania by June 26, 2023. Amerisourcebergen will provide the vials in support of the Defense Logistics Agency's medical supply chain initiatives. No subcontractors or set aside designations were identified. The delivery order...
- The Defense Logistics Agency (DLA) awarded a $34,902.10 firm fixed price delivery order to AmerisourceBergen Drug Corp for IPOL Vial 5ML pharmaceutical products on July 22, 2025, with an ultimate completion date of July 23, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger prime indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at approximately $1 billion and extending through December 2026. The delivery will be performed in...
- This delivery order, valued at $132,136, was awarded on July 21, 2025, to AmerisourceBergen Drug Corp for supply of Ipol vial 5ML pharmaceutical products. The contract, which is not set-aside and was competitively awarded, will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 22, 2025. The Defense Logistics Agency (DLA), which manages the federal medical supply chain, funded this award under firm fixed-price...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of IPOL VIAL 5ML medical products. The $1,796.20 contract has an ultimate completion date of August 23, 2022. Amerisourcebergen Drug Corp, through its Corporate Office Division, has been awarded this delivery order as part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp. for the supply of pharmaceutical products, specifically IPOL VIAL 5ML. The contract has a ceiling value of $1,067.35 and a total performance period through August 13, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor, has been awarded numerous federal contracts by defense and civilian agencies...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation's Corporate Office Division. The $17,077.60 firm fixed-price contract is for the delivery of 4565332558 IPOL VIAL 5ML pharmaceutical products. This order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a comprehensive range of medical commodities to support...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $12,645.16, is for the delivery of IPOL VIAL 5ML pharmaceutical products. It is a firm fixed-price contract with a period of performance through May 1, 2025. The contract is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWV60Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,652.21 to AmerisourceBergen Drug Corp for IPOL vial 5ML, a poliomyelitis vaccine product. The contract, executed on August 12, 2025, with an ultimate completion date of August 13, 2025, is a firm fixed price delivery order with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award represents a competitive procurement action under an existing contract vehicle. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates extensive capability in delivering critical medical commodities, including specialty medications, vaccines, and related medical supplies across multiple therapeutic domains to support Defense Health Agency requirements and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/12/25 |